CAMPTH-1H&TACROLIMUS FOLLOWED BY IMMUNOSUPPRESS WITHDRAWAL IN LIVER TRANSPLANTS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的目的是确定两剂CamPath-1H，然后是一种名为他克莫司(Prograf)的抗排斥药物，在预防供体肝脏排斥反应方面是否安全有效。这项研究还将评估Camath-1H诱导“耐受”的能力。耐受性是指即使你没有服用免疫抑制药，身体也不再试图排斥移植的肝脏。在这项研究中，用于预防排斥反应的抗排斥药物(他克莫司)将在肝移植后一年开始逐步停用，肝功能稳定。如果确定受试者可以逐步停用他克莫司，那么受试者将被重新同意参加这项研究的停用部分。停药部分将持续一年，包括每周和每两周一次的检查，以便逐步断奶他克莫司。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine if 2 doses of Campath-1H, followed by one anti-rejection drug called tacrolimus (Prograf), will be safe and effective in preventing rejection of the donor liver. This study will also evaluate the ability of the Campath-1H to induce "tolerance". Tolerance is when the body no longer tries to reject the transplanted liver even when you are not taking immunosuppression. During this study, the anti-rejection medication (tacrolimus) used to prevent rejection will be gradually withdrawn, beginning one year after liver transplant liver function is stable. If it is determined that the subject can gradually withdraw tacrolimus and then the subject will be re-consented to take part in the withdrawal portion of this study. The withdrawal component will last one year and involve weekly and bi-weekly visits to allow a gradual weaning of the tacrolimus.